Analysts Issue Forecasts for ENTA Q1 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – HC Wainwright issued their Q1 2025 earnings estimates for Enanta Pharmaceuticals in a report issued on Tuesday, December 24th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will post earnings of ($1.18) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.73) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2025 earnings at ($1.32) EPS, Q3 2025 earnings at ($1.45) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($5.54) EPS, FY2026 earnings at ($7.90) EPS, FY2027 earnings at ($8.00) EPS and FY2028 earnings at ($7.36) EPS.

A number of other equities research analysts have also weighed in on ENTA. Robert W. Baird decreased their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Up 0.2 %

ENTA stock opened at $6.01 on Friday. The firm has a market cap of $127.38 million, a price-to-earnings ratio of -1.10 and a beta of 0.49. Enanta Pharmaceuticals has a twelve month low of $5.70 and a twelve month high of $17.80. The business’s fifty day simple moving average is $9.15 and its two-hundred day simple moving average is $11.47.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The business had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business’s quarterly revenue was down 22.8% on a year-over-year basis. During the same quarter last year, the firm earned ($1.33) earnings per share.

Insider Buying and Selling

In other news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. This represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 13.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC acquired a new position in shares of Enanta Pharmaceuticals in the 2nd quarter valued at $35,000. US Bancorp DE grew its position in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 4,243 shares during the period. Quest Partners LLC increased its stake in shares of Enanta Pharmaceuticals by 511.2% in the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 9,692 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Enanta Pharmaceuticals in the 3rd quarter worth about $122,000. Finally, Valence8 US LP purchased a new position in Enanta Pharmaceuticals during the third quarter worth approximately $207,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.